Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab
Main Article Content
Keywords
pityriasis rubra pilaris, brodalumab, methotrexate
Abstract
Pityriasis Rubra Pilaris (PRP) is a rare inflammatory skin disease with highly variable clinical appearance. Treatment of PRP remains a challenge and has been mostly guided by case reports and case series. We report the first case of pityrisis rubra pilaris that is successfully treated with combination therapy of brodalumab and methotrexate.
References
2. Roenneberg, S, Biedermann, T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol 2018; 32( 6): 889– 898.
3. Griffiths, W. (1980), Pityriasis rubra pilaris*. Clinical and Experimental Dermatology, 5: 105-112. doi:10.1111/j.1365-2230.1980.tb01676.x
4. Ross NA, Chung H, Li Q, Andrews JK, Keller MS, Vitto J. Epidemiologic, clinicopathologic diagnostic and management challenges of pityriasis rubra pilaris: a case series of 103 patients. JAMA Dermatol. 2016;152(6):670-675
5. Wain T, Choy B, Satchell AC, Woods JA, Frew JW. Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep. 2018;4(5):500–505. Published 2018 May 7. doi:10.1016/j.jdcr.2018.02.007
6. Albert, M. R. and Mackool, B. T. (1999), Pityriasis rubra pilaris. International Journal of Dermatology, 38: 1-11. doi:10.1046/j.1365-4362.1999.00513
7. Klein A, Landthaler M, Karrer S. Pityriasis Rubra Pilaris. American Journal of Clinical Dermatology. 2010;11(3):157–170. doi:10.2165/11530070
8. Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304-308.
9. Barth, D. , Harth, W. , Treudler, R. and Simon, J. C. (2009), Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 7: 1071-1073. doi:10.1111/j.1610-0387.2009.07154.x
10. Wasilewska A, Winiarska M, Olszewska M, Rudnicka L. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33(4):247–252. doi:10.5114/ada.2016.61599
11. Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: A review of the literature. Journal of the American Academy of Dermatology. 2018;79(2):353-359.e11. doi:10.1016/j.jaad.2018.03.036
12. Moretta G, De Luca EV, Di Stefani A. Management of refractory pityriasis rubra pilaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2017;10:451–457. Published 2017 Nov 9. doi:10.2147/CCID.S124351
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.